152 related articles for article (PubMed ID: 19546410)
1. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis.
Clement FM; Klarenbach S; Tonelli M; Johnson JA; Manns BJ
Arch Intern Med; 2009 Jun; 169(12):1104-12. PubMed ID: 19546410
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Collister D; Komenda P; Hiebert B; Gunasekara R; Xu Y; Eng F; Lerner B; Macdonald K; Rigatto C; Tangri N
Ann Intern Med; 2016 Apr; 164(7):472-8. PubMed ID: 26881842
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
6. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis.
Guedes M; Guetter CR; Erbano LHO; Palone AG; Zee J; Robinson BM; Pisoni R; de Moraes TP; Pecoits-Filho R; Baena CP
BMC Nephrol; 2020 Jul; 21(1):259. PubMed ID: 32641153
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
8. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
9. Association of anemia correction with health related quality of life in patients not on dialysis.
Alexander M; Kewalramani R; Agodoa I; Globe D
Curr Med Res Opin; 2007 Dec; 23(12):2997-3008. PubMed ID: 17958944
[TBL] [Abstract][Full Text] [Related]
10. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P
J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537
[TBL] [Abstract][Full Text] [Related]
11. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
Kimel M; Leidy NK; Mannix S; Dixon J
Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
[TBL] [Abstract][Full Text] [Related]
12. Anemia, inflammation and health-related quality of life in chronic kidney disease patients.
Farag YM; Keithi-Reddy SR; Mittal BV; Surana SP; Addabbo F; Goligorsky MS; Singh AK
Clin Nephrol; 2011 Jun; 75(6):524-33. PubMed ID: 21612756
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients.
Johansen KL; Finkelstein FO; Revicki DA; Evans C; Wan S; Gitlin M; Agodoa IL
Nephrol Dial Transplant; 2012 Jun; 27(6):2418-25. PubMed ID: 22187314
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
Hertel JE; Locay HR; Scarlata DS; Prathikanti R; Audhya PK
Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
[TBL] [Abstract][Full Text] [Related]
15. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
16. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of darbepoietin alfa in anemic patients with chronic kidney disease (CKD) in predialysis period].
Wanic-Kossowska M; Tykarski A; Kobelski M; Czekalski S
Pol Arch Med Wewn; 2006 Jul; 116(1):663-70. PubMed ID: 17340973
[TBL] [Abstract][Full Text] [Related]
18. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat.
Tang M; Zhu C; Yan T; Zhou Y; Lv Q; Chuan J
Front Pharmacol; 2021; 12():658079. PubMed ID: 34276361
[No Abstract] [Full Text] [Related]
19. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
20. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
